Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax for acute graft-versus-host disease after allogeneic HSCT
2025-520545-74-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Medical University of Vienna. Primary endpoint: Maximum tolerated dose after 28 and 56 days. Planned start Nov 2025; status: authorised.
02
Drugs
venetoclax
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2025-520545-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520545-74-00.